Related Experiment Video
Updated: Jun 18, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Advancing Cystic Fibrosis-Related Diabetes Care With Automated Insulin Delivery Systems
Valeria Grancini1, Gianfranco Alicandro2, Irene Cogliati1
1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Endocrinology Unit, Milan, Italy.
Clinical Therapeutics
|June 16, 2026
Summary
Automated insulin delivery (AID) significantly improved treatment satisfaction and quality of life for adults with cystic fibrosis-related diabetes (CFRD). This technology offers a promising new approach to managing CFRD, a common complication of cystic fibrosis.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Respiratory Medicine
Background:
- Cystic fibrosis-related diabetes (CFRD) is the most prevalent comorbidity in cystic fibrosis (CF), linked to accelerated lung function decline and increased mortality.
- Current insulin therapy for CFRD faces challenges due to variable insulin requirements and the significant burden of CF care.
- Automated insulin delivery (AID) systems present a potential solution for enhancing glycemic control and patient quality of life (QoL) in CFRD, but clinical evidence is limited.
Purpose of the Study:
- To evaluate the impact of transitioning to AID from multiple daily injections (MDI) or sensor-augmented pump (SAP) therapy on treatment satisfaction and diabetes-specific QoL in adults with CFRD.
Main Methods:
- A prospective cohort study involving 21 adults with CFRD who switched to AID from MDI or SAP.
- Patients completed the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and Audit of Diabetes-Dependent Quality of Life (ADDQoL) at baseline and after 3 months.
- Continuous glucose monitoring (CGM) metrics were assessed as secondary outcomes.
Main Results:
- Significant improvements were observed in DTSQ scores (22 to 33, P < 0.001) and ADDQoL scores (-2.1 to -0.9, P < 0.001) after 3 months of AID use.
- Continuous glucose monitoring (CGM) metrics also demonstrated significant improvements, indicating better glycemic control.
- These results suggest a positive patient-reported outcome and physiological response to AID therapy.
Conclusions:
- Automated insulin delivery (AID) shows preliminary promise as an effective tool for managing cystic fibrosis-related diabetes (CFRD).
- The study indicates that AID can enhance treatment satisfaction and quality of life in adults with CFRD.
- Further research is warranted to confirm these findings in larger cohorts.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...